📰 Mandy Fahey News
Page 2 - Mandy Fahey News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Mandy Fahey. Real-time updates on events, politics, business and more.
January 5, 2024
—ARIKAYCE® (amikacin liposome inhalation suspension) Delivers Full-Year 2023 Revenues Exceeding the Upper End of Guidance Range with Unaudited Global Net...
January 2, 2024
BRIDGEWATER, N.J., Jan. 2, 2024 /PRNewswire/ -- Insmed Incorporated , a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today...
November 3, 2023
BRIDGEWATER, N.J., Nov. 3, 2023 /PRNewswire/ -- Insmed Incorporated , a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today...
October 26, 2023
—ARIKAYCE® Total Revenue of $79.1 Million for the Third Quarter of 2023 Reflects Highest Quarter of Sales Since Launch and 17% Growth Compared to the Third Quarter of 2022— —Company...
October 26, 2023
/PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare...
October 26, 2023
Insmed Incorporated , a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced that it has earned the highest ranking in Science's 2023 Top Employers Survey. The annual survey...
October 6, 2023
BRIDGEWATER, N.J., Oct. 6, 2023 /PRNewswire/ -- Insmed Incorporated , a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today...
September 8, 2023
/PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare...
August 4, 2023
/PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare...
August 3, 2023
-- ARIKAYCE® (amikacin liposome inhalation suspension) Total Revenue of $77.2 Million for the Second Quarter of 2023 Reflects Highest Quarter of Sales Since...